NASDAQ: FDMT
4d Molecular Therapeutics Inc Stock Ownership - Who owns 4d Molecular Therapeutics?

Insider buying vs selling

Have 4d Molecular Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Scott BizilyChief Legal Officer2025-11-171,635$4.14
$6.77kBuy
Scott BizilyChief Legal Officer2025-11-171,635$10.59
$17.31kSell
Scott BizilyChief Legal Officer2025-10-241,084$6.49
$7.04kBuy
Scott BizilyChief Legal Officer2025-10-242,678$12.00
$32.14kSell
Scott BizilyChief Legal Officer2025-10-161,635$4.14
$6.77kBuy
Scott BizilyChief Legal Officer2025-10-161,635$10.17
$16.63kSell
Scott BizilyChief Legal Officer2025-10-092,408$10.00
$24.08kSell
Scott BizilyChief Legal Officer2025-09-232,407$8.00
$19.26kSell

1 of 1

FDMT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FDMT insiders and whales buy or sell their stock.

FDMT Shareholders

What type of owners hold 4d Molecular Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bvf Inc8.10%4,629,289$53.98MInstitution
Ra Capital Management LP7.99%4,563,211$53.21MInsider
Ra Capital Management LP7.99%4,563,211$53.21MInstitution
Viking Global Investors LP7.43%4,247,914$49.53MInsider
Goldman Sachs Group Inc7.23%4,128,416$48.14MInstitution
Blackrock Inc6.77%3,869,130$45.11MInstitution
Vanguard Group Inc4.51%2,575,122$30.03MInstitution
Novo Holdings A3.50%2,000,000$23.32MInstitution
Janus Henderson Group PLC3.07%1,753,367$20.44MInstitution
David Kirn2.90%1,659,153$19.35MInsider

1 of 3

FDMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FDMT69.15%22.21%Net SellingNet Selling
IVVD61.79%38.21%Net SellingNet Buying
JBIO62.53%37.47%Net BuyingNet Buying
MGTX56.35%43.65%Net SellingNet Selling
PRME44.61%55.39%Net Buying

4d Molecular Therapeutics Stock Ownership FAQ

Who owns 4d Molecular Therapeutics?

4d Molecular Therapeutics (NASDAQ: FDMT) is owned by 69.15% institutional shareholders, 22.21% 4d Molecular Therapeutics insiders, and 8.64% retail investors. Ra Capital Management LP is the largest individual 4d Molecular Therapeutics shareholder, owning 4.56M shares representing 7.99% of the company. Ra Capital Management LP's 4d Molecular Therapeutics shares are currently valued at $47.96M.

If you're new to stock investing, here's how to buy 4d Molecular Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.